Loading...

ABCL ABCELLERA BIOLOGICS INC US FDA Inspections 8-K Filing

BCLL

BCL

ABCELLERA BIOLOGICS INC

(ABCL)

2025 8-K

Show Summary

Summary

Financial Statements

Clinical Trials

Clinical Trials

Regulatory Compliance

Financial Statements

Earnings Results

Management Change

Earnings Announcement

Earnings Reports

Annual Meeting of Shareholders

Departure of Directors

Financial Results Announcement

Workforce Reduction

Ownership of Antibody Drug ...

Annual Meeting of Shareholders

Investment Agreement

Regulation FD Disclosure

External Links:

On May 30, 2025, AbCellera Biologics Inc. announced they received a No Objection Letter from Health Canada to proceed with a clinical trial for their new drug ABCL575 aimed at treating moderate-to-severe atopic dermatitis. This drug could also help with other inflammatory and autoimmune conditions.

AI Assistant

ABCELLERA BIOLOGICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.